Format

Send to

Choose Destination
See comment in PubMed Commons below
J Pharmacol Toxicol Methods. 2013 Nov-Dec;68(3):334-9. doi: 10.1016/j.vascn.2013.07.004. Epub 2013 Aug 3.

Accelerated Caco-2 cell permeability model for drug discovery.

Author information

1
Univ Lille Nord de France, Lille, France; UArtois, LBHE, Lens, France; IMPRT-IFR114, Lille, France.

Abstract

INTRODUCTION:

By culturing Caco-2 cells according to a new and optimized protocol, it has been possible to accelerate the cell culture process in such a way that the cells can be used for experiments after only 6 days. The accelerated Caco-2 model has been compared to the traditional model (requiring 21-25 days of culture) in terms of tightness of the junctions, ability to rank chemical compounds for apparent permeability, active efflux and to discriminate P-gp substrates.

METHODS AND RESULTS:

In the new protocol, Caco-2 cells were cultured with the classical Caco-2 medium supplemented with puromycin. The initial cell seeding density was increased two times compared to the traditional procedure and the presence of a low concentration of puromycin in the culture medium reduced the Caco-2 permeability of mannitol. Bi-directional studies were performed with known P-gp substrates (rhodamine 123, digoxin and saquinavir) and with a total of 20 marketed drugs covering a wide range of physicochemical characteristics and therapeutic indications. Strong correlations were obtained between the apparent permeability in absorptive (Papp A→B) or secretory (Papp B→A) of the drugs in the accelerated model and in the traditional models and comparable efflux ratios were observed in the two studied models.

DISCUSSION:

The new protocol reduces costs for screening and leads to higher throughput compared to traditional Caco-2 cell models. This accelerated model provides short time-feedback to the drug design during the early stage of drug discovery.

KEYWORDS:

Accelerated model; Caco-2 cells; Drug discovery; Drug permeability; Efflux ratio; P-glycoprotein; Puromycin

PMID:
23916595
DOI:
10.1016/j.vascn.2013.07.004
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center